Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hansoh In-licenses Novel Anti-Viral from NiKang in Deal Worth up to $100 Million Plus

publication date: Apr 23, 2020

Hansoh, a Shanghai Pharma, in-licensed greater China rights to a small molecule anti-viral from NiKang Therapeutics of Delaware in a deal potentially worth more than $100 million. NKT-1992 targets a highly conserved enzymatic domain that is critical for viral transcription and replication. According to NiKang, its target selection is driven by insights into disease biology, and its small molecule candidates are discovered using structure-based design. More details....

Stock Symbol: (HK; 3692)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.